MAY 26, 2023
Renatus, Carbohyde sign MOU to co-develop novel cholesterol modulators for CNS disease applications.
APRIL 20, 2023
Renatus was selected for the Scale-Up Challenge Lab program by Incheon Startup Park.
MARCH 17, 2023
Renatus has been granted a key patent for novel cyclodextrins for the treatment of cholesterol-driven diseases by Korea Intellectual Property Office (KIPO).
JANUARY 2, 2023
Renatus was selected for the HBIC program by Korea Health Industry Development Institute (KHIDI).
JULY 25, 2022
Renatus was selected for the Startup-Focused University Program by Ministry of SMEs and Startups.
MAY 25, 2022
Renatus was selected for the Smart-X Bio program by Incheon Startup Park to support innovative bio startups.
MARCH 15, 2022
JANUARY 23, 2022
Renatus, a pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases, today opened its official website to public.